Pitavastatin Availability: What Providers and Prescribers Need to Know in 2026

Pitavastatin (Livalo, Zypitamag) occupies a unique niche in the statin class — a moderate-intensity agent with a distinct pharmacokinetic profile, lower diabetes risk, and fewer drug interactions via CYP3A4. While it is not subject to a formal FDA-declared shortage, clinicians increasingly encounter patient reports of difficulty filling pitavastatin prescriptions. This briefing summarizes the current supply landscape, insurance considerations, cost management tools, and evidence-based prescribing strategies for 2026.

Current Supply Status

As of 2026, pitavastatin is not listed on the FDA Drug Shortage Database or the ASHP Drug Shortages Resource Center. No national manufacturing shortage exists. Generic pitavastatin is produced by multiple manufacturers and is commercially available through standard pharmaceutical distribution channels.

However, patient-reported access difficulties reflect a structural issue in the retail pharmacy market: because pitavastatin is prescribed at significantly lower volumes than atorvastatin or rosuvastatin, many retail pharmacies stock it minimally or do not carry it at all. This demand-driven understocking — rather than a supply chain disruption — is the primary driver of patient access problems.

Why Pitavastatin Access Matters Clinically

Pitavastatin is not an interchangeable commodity statin. Providers typically prescribe it for specific reasons that have real clinical implications if the patient switches to an alternative:

• Glycemic profile: Pitavastatin appears to have a more favorable effect on fasting glucose and HbA1c compared to rosuvastatin and atorvastatin, making it the preferred statin for patients with prediabetes or T2DM where statin-related glycemic effects are a concern.
• Drug-drug interactions: Pitavastatin is minimally metabolized by CYP3A4 and relies primarily on OATP1B1/1B3 hepatic transporters. This makes it preferable over simvastatin and lovastatin — and often over atorvastatin — in patients on CYP3A4-sensitive medications (azole antifungals, macrolide antibiotics, calcium channel blockers, etc.).
• HIV antiretroviral therapy: Pitavastatin is among the preferred statins for PLHIV on ART, given reduced pharmacokinetic interactions with most commonly used antiretrovirals compared to atorvastatin.
• Pediatric HeFH: Livalo (pitavastatin calcium) is FDA-approved for children age 8 and older with heterozygous familial hypercholesterolemia — an important option in this underserved population.

Formulary and Insurance Considerations

Insurance coverage for pitavastatin is a significant access barrier. Most Medicare Part D formularies and commercial insurance plans either exclude pitavastatin entirely or place it on a high formulary tier (Tier 3 or Non-Preferred), requiring prior authorization or step therapy through preferred statins first.

If you have a clinical indication for pitavastatin in a patient whose formulary does not cover it, document the medical necessity clearly in the prior authorization request. Common grounds for approval include: documented CYP3A4 drug interactions with preferred statin alternatives, statin-related glucose elevations requiring a lower-risk agent, or previous adverse reactions to covered statins.

Cost Resources for Patients Who Can't Afford Pitavastatin

Without insurance coverage, pitavastatin's retail cost can exceed $330-$440 per month. However, several programs dramatically reduce this cost:

• Livalo Savings Program: Eligible commercially insured and cash-paying patients may pay as low as $25/month for brand Livalo. Call 844-567-9504 or direct patients to the program website.
• GoodRx / SingleCare coupons: Generic pitavastatin can be obtained for $36-$47 at many pharmacies with these discount cards. These work in lieu of insurance and are available to all patients.
• Cost Plus Drugs: Transparent pricing model often below retail coupon prices. Worth checking for your patient's specific dose.

39,018+ patients found their medications in stock

39K+

Find Pitavastatin In Stock Today →

Key Drug Interactions to Review Before Prescribing

While pitavastatin has fewer CYP-mediated interactions than many statins, its OATP transporter-dependent hepatic uptake creates clinically significant interactions:

• Cyclosporine (contraindicated): OATP1B1 inhibition dramatically increases pitavastatin AUC, raising rhabdomyolysis risk. Avoid concomitant use.
• Gemfibrozil (not recommended): Similar OATP inhibition with significant myopathy risk. Use fenofibrate instead if a fibrate is necessary.
• Erythromycin: Limit pitavastatin to 1 mg/day. Consider azithromycin as an alternative antibiotic when possible.
• Rifampin: Limit pitavastatin to 2 mg/day due to unpredictable OATP effects.
• Letermovir + cyclosporine: Contraindicated. When letermovir is co-administered with cyclosporine, pitavastatin is contraindicated.

Therapeutic Alternatives If Pitavastatin Is Inaccessible

If a patient cannot access pitavastatin due to cost or pharmacy availability, consider these evidence-based alternatives based on the original clinical indication:

• Diabetes/glycemic concern: Pravastatin has the most favorable glycemic profile among widely available statins. If high-intensity therapy is needed, discuss the risk-benefit with the patient.
• CYP3A4 interaction concern: Rosuvastatin (CYP2C9, minimal) or pravastatin (no CYP metabolism) are the best non-CYP3A4 alternatives.
• HIV/ART patients: Pravastatin is well-studied in this population; rosuvastatin is also acceptable in most ART regimens. Review specific antiretroviral combinations with clinical pharmacy.

Skip the calls, skip the stress.

Find Pitavastatin In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Helping Patients Find Pitavastatin at Their Pharmacy

When patients need help locating pitavastatin at a nearby pharmacy, direct them to medfinder for providers. medfinder calls local pharmacies to check current stock and texts results to the patient — eliminating the time patients spend on hold while trying to fill a hard-to-find prescription.

For a detailed provider protocol, see: How to Help Your Patients Find Pitavastatin In Stock: A Provider's Guide